CMS (00867.HK): Opzelura-Counterpart Baicor (Ruxolitinib Cream) Approved for Atopic Dermatitis in China

NewTimeSpace News: On 3 September 2026, China Medical System Holdings Limited (stock code: 00867) announced that its skin-health focused subsidiary Deme Medical obtained approval from the National Medical Products Administration (NMPA) on 2 September 2026 for the new drug application of ruxolitinib phosphate cream Baicor for mild-to-moderate atopic dermatitis (AD), and received the drug registration certificate on 3 September 2026. The product is indicated for short-term and non-continuous chronic topical treatment of mild-to-moderate AD in non-immunocompromised children aged 2 years and above and adults where other topical treatments are poorly controlled or not recommended, and was granted priority review as a paediatric-friendly new drug.

According to the announcement, Baicor became the first topical JAK inhibitor approved in China for vitiligo in January 2026, and this approval marks its expansion into a second indication. 

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.